Cargando…
Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape
Any time the pharmaceutical industry develops a new drug, potential polymorphic events must be thoroughly described, because in a crystalline pharmaceutical solid, different arrangements of the same active pharmaceutical ingredient can yield to very different physicochemical properties that might be...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706418/ https://www.ncbi.nlm.nih.gov/pubmed/34959421 http://dx.doi.org/10.3390/pharmaceutics13122140 |
_version_ | 1784622187705008128 |
---|---|
author | Acebedo-Martínez, Francisco Javier Alarcón-Payer, Carolina Frontera, Antonio Barbas, Rafael Prohens, Rafel Di Crisci, Milena Domínguez-Martín, Alicia Gómez-Morales, Jaime Choquesillo-Lazarte, Duane |
author_facet | Acebedo-Martínez, Francisco Javier Alarcón-Payer, Carolina Frontera, Antonio Barbas, Rafael Prohens, Rafel Di Crisci, Milena Domínguez-Martín, Alicia Gómez-Morales, Jaime Choquesillo-Lazarte, Duane |
author_sort | Acebedo-Martínez, Francisco Javier |
collection | PubMed |
description | Any time the pharmaceutical industry develops a new drug, potential polymorphic events must be thoroughly described, because in a crystalline pharmaceutical solid, different arrangements of the same active pharmaceutical ingredient can yield to very different physicochemical properties that might be crucial for its efficacy, such as dissolution, solubility, or stability. Polymorphism in cocrystal formulation cannot be neglected, either. In this work, two different cocrystal polymorphs of the non-steroidal anti-inflammatory drug niflumic acid and caffeine are reported. They have been synthesized by mechanochemical methods and thoroughly characterized in solid-state by powder and single crystal X-ray diffraction respectively, as well as other techniques such as thermal analyses, infrared spectroscopy and computational methods. Both theoretical and experimental results are in agreement, confirming a conformational polymorphism. The polymorph NIF–CAF Form I exhibits improved solubility and dissolution rate compared to NIF–CAF Form II, although Form II is significantly more stable than Form I. The conditions needed to obtain these polymorphs and their transition have been carefully characterized, revealing an intricate system. |
format | Online Article Text |
id | pubmed-8706418 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87064182021-12-25 Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape Acebedo-Martínez, Francisco Javier Alarcón-Payer, Carolina Frontera, Antonio Barbas, Rafael Prohens, Rafel Di Crisci, Milena Domínguez-Martín, Alicia Gómez-Morales, Jaime Choquesillo-Lazarte, Duane Pharmaceutics Article Any time the pharmaceutical industry develops a new drug, potential polymorphic events must be thoroughly described, because in a crystalline pharmaceutical solid, different arrangements of the same active pharmaceutical ingredient can yield to very different physicochemical properties that might be crucial for its efficacy, such as dissolution, solubility, or stability. Polymorphism in cocrystal formulation cannot be neglected, either. In this work, two different cocrystal polymorphs of the non-steroidal anti-inflammatory drug niflumic acid and caffeine are reported. They have been synthesized by mechanochemical methods and thoroughly characterized in solid-state by powder and single crystal X-ray diffraction respectively, as well as other techniques such as thermal analyses, infrared spectroscopy and computational methods. Both theoretical and experimental results are in agreement, confirming a conformational polymorphism. The polymorph NIF–CAF Form I exhibits improved solubility and dissolution rate compared to NIF–CAF Form II, although Form II is significantly more stable than Form I. The conditions needed to obtain these polymorphs and their transition have been carefully characterized, revealing an intricate system. MDPI 2021-12-13 /pmc/articles/PMC8706418/ /pubmed/34959421 http://dx.doi.org/10.3390/pharmaceutics13122140 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Acebedo-Martínez, Francisco Javier Alarcón-Payer, Carolina Frontera, Antonio Barbas, Rafael Prohens, Rafel Di Crisci, Milena Domínguez-Martín, Alicia Gómez-Morales, Jaime Choquesillo-Lazarte, Duane Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape |
title | Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape |
title_full | Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape |
title_fullStr | Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape |
title_full_unstemmed | Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape |
title_short | Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape |
title_sort | novel polymorphic cocrystals of the non-steroidal anti-inflammatory drug niflumic acid: expanding the pharmaceutical landscape |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706418/ https://www.ncbi.nlm.nih.gov/pubmed/34959421 http://dx.doi.org/10.3390/pharmaceutics13122140 |
work_keys_str_mv | AT acebedomartinezfranciscojavier novelpolymorphiccocrystalsofthenonsteroidalantiinflammatorydrugniflumicacidexpandingthepharmaceuticallandscape AT alarconpayercarolina novelpolymorphiccocrystalsofthenonsteroidalantiinflammatorydrugniflumicacidexpandingthepharmaceuticallandscape AT fronteraantonio novelpolymorphiccocrystalsofthenonsteroidalantiinflammatorydrugniflumicacidexpandingthepharmaceuticallandscape AT barbasrafael novelpolymorphiccocrystalsofthenonsteroidalantiinflammatorydrugniflumicacidexpandingthepharmaceuticallandscape AT prohensrafel novelpolymorphiccocrystalsofthenonsteroidalantiinflammatorydrugniflumicacidexpandingthepharmaceuticallandscape AT dicriscimilena novelpolymorphiccocrystalsofthenonsteroidalantiinflammatorydrugniflumicacidexpandingthepharmaceuticallandscape AT dominguezmartinalicia novelpolymorphiccocrystalsofthenonsteroidalantiinflammatorydrugniflumicacidexpandingthepharmaceuticallandscape AT gomezmoralesjaime novelpolymorphiccocrystalsofthenonsteroidalantiinflammatorydrugniflumicacidexpandingthepharmaceuticallandscape AT choquesillolazarteduane novelpolymorphiccocrystalsofthenonsteroidalantiinflammatorydrugniflumicacidexpandingthepharmaceuticallandscape |